A novel Salmonella Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer
Authors:
- Alejandrina VendrellAVAlejandrina Vendrell
- María J. GravisacoMGMaría J. Gravisaco
- Marcela F. PasettiMPMarcela F. Pasetti
- Máximo CrociMCMáximo Croci
- Lucas ColomboLCLucas Colombo
- Carla RodríguezCRCarla Rodríguez
- Claudia MonginiCMClaudia Mongini
- Claudia I. WaldnerCWClaudia I. Waldner
Abstract
No abstract availableKeywords
Funding Information
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
This publication has 38 references indexed in Scilit:
- Attenuated Bacteria as Effectors in Cancer ImmunotherapyAnnals of the New York Academy of Sciences, 2008
- Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancerProceedings of the National Academy of Sciences, 2007
- Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanomaThe Journal of Gene Medicine, 2007
- Intralymphatic Dendritic Cell Vaccination Induces Tumor Antigen–Specific, Skin-Homing T LymphocytesClinical Cancer Research, 2006
- Targeted Therapy with aSalmonella TyphimuriumLeucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude MiceCancer Research, 2006
- Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor CellsCancer Research, 2005
- Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 2004
- Tumors as elusive targets of T-cell-based active immunotherapyTrends in Immunology, 2003
- Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella TyphimuriumJournal of Immunotherapy, 2002
- Can engineered bacteria help control cancer?Proceedings of the National Academy of Sciences, 2001